Few medications have gotten as much attention as semaglutide. The injectable drug, which is sold under the brand names Wegovy ...

About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was ...

Patients who took the frequently prescribed diabetes and weight-loss drugs Ozempic and Wegovy faced a greater risk of a ...

The risk of developing non-arteritic anterior ischemic optic neuropathy is four times higher for diabetics on semaglutide and seven times higher for people taking the drug to lose weight ...

Increased risk for NAION seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. HealthDay News — Semaglutide is associated with nonarteritic anterior ...

After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data ...

People who take semaglutide—the active ingredient in Ozempic and Wegovy—may have a higher risk of a rare eye condition called ...

New research led by the Massachusetts Eye and Ear Hospital (Mass Eye and Ear) found that semaglutide use was associated with nonarteritic anterior ischemic optic neuropathy (NAION), or ‘eye ...

as was shown in the ONTT for optic neuritis. Unfortunately, there are many limitations to our study. The major limitation is the retrospective nature of this study which does not allow deducing ...

Over a mean follow-up of nearly 3 years, patients with diabetes on semaglutide had more than a fourfold higher risk for developing nonarteritic anterior ischemic optic neuropathy (NAION ...

By Tarun Sai Lomte A recent study published in the journal JAMA Ophthalmology evaluated associations between semaglutide and ...